III — The Gut Cluster
Laurel Fitzhugh — September 16, 2026 | Status: Overview, substantially revised
This document orients the references that make up the gut cluster. Each addresses a different layer of the same system; together they form the case for how gut-barrier dysfunction drives systemic inflammatory amplification throughout this clinical picture.
This overview previously treated stool-based microbiome sequencing as load-bearing evidence — specifically, a claimed “locked pathological attractor state” confirmed across two metagenomic draws. That claim is retired. The barrier-dysfunction mechanism itself is not; it now rests on different evidence than it did before.
On microbiome testing
Three platforms have now been tried, and each has failed in a different way. Thorne used a novel collection wipe, with environmental organisms (Streptomyces, Cupriavidus) appearing at levels inconsistent with genuine human stool composition. Jona showed outright data fabrication — hierarchical abundance inflation with relative-abundance sums exceeding 800%, and zero non-bacterial organisms detected despite a reference database containing thousands of viral and parasitic entries. Biomesight uses 16S sequencing, which has real taxonomic resolution limits compared to shotgun methods even when the data itself is honest.
That is not one bad kit. It is every kit tried, failing differently. A reasonable person updates hard on that pattern. Stool metagenomics as a category has known reproducibility problems even in research settings — inter-lab variability, extraction-method sensitivity, reference-database inconsistency — and three separate, distinct manifestations of that instability have now been hit personally, across three platforms.
Combined with the practical reality that no clinician is currently accessible to act on a microbiome result even if one were trustworthy, stool sequencing is no longer treated as an actionable data source in this document set. What is not known: the actual current state of microbial composition, its severity, or its specific character. That is a genuine unknown, not a resolved-negative — the position here is “unmeasurable with available tools,” not “the gut is fine.”
III-a. Gut Foundational — the mechanistic foundation
Establishes intestinal barrier dysfunction as a distinct driver of systemic inflammation, re-anchored to evidence that does not depend on microbiome sequencing: colonoscopy-confirmed mucosal pathology (biopsy, not sequencing), persistently elevated IgA, celiac serology positive against negative histology, and the symptom-timing pattern in which food triggers produce systemic joint and muscle inflammation within hours rather than local GI symptoms — consistent with antigen translocation across a compromised barrier. This is the baseline gut-immune picture against which the other two documents describe specific interventions and events, built on evidence that holds regardless of what any stool test says.
III-b. Helminthic Therapy — the partial restoration and its limits
Documents the mechanism and clinical course of Necator americanus colonization since 2020, inferred from symptom response rather than from before/after microbiome snapshots: the Th2 immune skewing and barrier-reinforcing effects that produced sustained functional improvement and medication-sparing benefit through 2023. Following the 2024 dysbiosis event, HT’s apparent stabilizing effect diminished — but colonization has been continuous and undisturbed throughout, so the more coherent read is an increase in the inflammatory load HT’s regulatory mechanisms are working against, not a reduction in HT’s own activity. This is the intervention that worked, and largely still does, against a job that appears to have gotten bigger.
III-c. Iron-Triggered Dysbiosis — Working Hypothesis and Current Status
Documents the 2023–2024 IV iron infusions as the proximate trigger for a subsequent symptomatic escalation — RA escalation, new chronic urticaria, microscopic colitis symptom recurrence — established as a clinical timeline, not as a confirmed microbial-composition event. What is no longer claimed: that two metagenomic draws (Thorne, 2024 and 2025) independently confirmed a locked pathological microbiome state. Those two draws were the same discontinued platform, not independent tests, and two genuinely independent current-state tests (Jona, June 2026; Biomesight, August 2026) do not corroborate that architecture. What remains solid: the temporal sequence (iron infusions, then escalation) and the clinical/symptomatic consequences that followed across multiple previously stable systems. What is genuinely unknown: whether, or how, the microbiome itself changed in composition — that question is currently unanswerable with available tools.
Read together, the sequence is foundation → intervention → disruption: a baseline gut-immune mechanism evidenced by biopsy and serology, a therapy that worked within that mechanism, and an event that preceded a symptomatic escalation whose microbial character cannot currently be established. This overview exists only to show how the three connect, and to anchor where future gut-cluster documents would slot in.